TuHURA Biosciences, Inc./NV
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
HURA$1.51-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Research and development expenses | $6,620,323 | $4,926,936 | $11,852,864 | $9,508,608 |
| Acquisition-related costs | - | 3,086,982 | - | 3,506,025 |
| General and administrative expenses | 2,142,961 | 1,862,038 | 4,440,319 | 3,878,346 |
| Operating Loss | (8,763,284) | (9,875,956) | (16,293,183) | (16,892,979) |
| Other (Expense) Income: | ||||
| Grant income | - | 322,655 | - | 575,209 |
| Interest expense | (467,634) | - | (495,608) | - |
| Interest income | 7,620 | 29,466 | 28,895 | 129,564 |
| Total Other (Expense) Income | (460,014) | 352,121 | (466,713) | 704,773 |
| Net Loss | $(9,223,298) | $(9,523,835) | $(16,759,896) | $(16,188,206) |
| Series A Preferred cash dividend | (2,089) | (2,089) | (4,178) | (4,178) |
| Net Loss attributable to common stockholders | $(9,225,387) | $(9,525,924) | $(16,764,074) | $(16,192,384) |
| Net Loss per share, basic and diluted | $(0.14) | $(0.21) | $(0.27) | $(0.36) |
| Weighted-average shares outstanding, basic and diluted | 63,963,513 | 44,555,095 | 61,997,795 | 44,983,198 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.